Assessment of Automatic Relays by Intensive Basis Advantage Compared With Manual Relays, on the Hypotension Risks, During Noradrenalin Administration
Information source: Centre Hospitalier Departemental Vendee
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypotension
Intervention: Measure of arterial pressure (Procedure)
Phase: N/A
Status: Completed
Sponsored by: Centre Hospitalier Departemental Vendee Official(s) and/or principal investigator(s): Jean Reignier, MD, Principal Investigator, Affiliation: CHD Vendée
Summary
Circulatory failures are the main cause of admissions in the intensive care unit. It is
recommended to prescribe to these patients an intravenous injection of catecholamine to
correct this dysfunction and to keep an hemodynamic stability. Electric pumps are used to
administrate a continuous flow of drugs to patient. When a syringe of drugs ends, it is
replaced by a full syringe, it is named "relay". This change may cause a flow interruption
and hypotension.
In the intensive care unit at departmental hospital (CHD) Vendee, the manual relays used in
common practice will cause hemodynamic instabilities : hypotensions in 20% cases. Since 4
years, new devices are also used to make the relays. It is "smart pumps" allowing to manage
automated the drug delays. This new method allows to not interrupt the drug flow. It could
reduce the occurence of hypotension. A 50% decrease of relative number of hypotension will
show that the use of automatic method is the most sure medical strategy.
Our study want to compare manual and automatic method watching the variations of medium
arterial pressure (MAP) during the fifteen minutes after the relay compared to baseline (MAP
before the relay). Noradrenalin is the catecholamine most administrated so we choose to
study only the relay for this drug.
Clinical Details
Official title: Assessment of Automatic Relays by Intensive Basis Advantage Compared With Manual Relays, on the Hypotension Risks, During Noradrenalin Administration
Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Primary outcome: Hypotension occurence defined as a decrease of 20% of the medium arterial pressure(MAP) between the baseline (MAP before the relay) and the minimal MAP in the fifteen minutes after the relay.
Secondary outcome: Number of relays where the medium arterial pressure (MAP) is decreased by 10% compared to baselineNumber of relays where the medium arterial pressure (MAP) is inferior to 50 millimeter of mercury (mmHg) Number of hypotension in patients whose dose of noradrenalin is > 0,5 gamma/kg/min
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patient > 18 years,
- Patient receiving only noradrenalin as catecholamine,
- Collection of patient's non-objection or his trustworthy person, if appropriate.
Exclusion Criteria:
- Pregnant or breast feeding patient,
- Patient receiving an other treatment on the catecholamine way,
- No affiliation at a social security,
- Refusal of patient's trustworthy person or parent, if the patient is unable to give
his non-objection.
- Refusal of patient's participation when he is conscious,
- Subjects deprived of liberty, under guardianship, hospitalized in a health facility
or social or hospitalized without their consent,
- Patients with secreting tumor, kind pheochromocytoma ou carcinoid tumor.
Locations and Contacts
CHD Vendée, La Roche sur Yon, Vendée 85925, France
Additional Information
Starting date: June 2009
Last updated: November 20, 2012
|